Q-omics provides the consensus-scored NXF3 profile across patient tissues and cancer cell-line models. NXF3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NXF3 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, NXF3 RNA expression shows 9,618 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUSC, and ESCA as cancer lineages where NXF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXF3 survival associations across molecular data types. NXF3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXF3 RNA expression–survival associations across cancer types. High NXF3 expression shows unfavorable associations in KIRC, BRCA, STAD, KIRP, LGG and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NXF3 RNA expression.
This table summarizes NXF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NXF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXF3 shows lower tumor expression in LUSC, LUAD, KIRC, LIHC and KICH and higher tumor expression in THCA. The LUSC box plot shows higher NXF3 RNA expression in normal versus tumor tissue (log2 FC = −2.240, t-test p < 0.001).
This table shows molecular features associated with NXF3 in patient tissues and cancer cell lines. In patient samples, NXF3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NXF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
